[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jinling Hospital, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":650},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,49,73,102,132,157,182,208,228,256,279,312,348,367,388,415,433,460,482,505,531,554,576,603,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644733","phase-2-perioperative-ursodeoxycholic-acid-for-renal-protection-in-adults-undergoing-partial-nephrectomy-for-renal-tumors-100644733",false,"NCT07672860","Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors","Protective Effect of Perioperative Ursodeoxycholic Acid Intervention Against Ischemia-Reperfusion Injury During Partial Nephrectomy: A Single-Center, Prospective, Double-Blind, Randomized Controlled Trial (PURIFY Trial)","PURIFY","1\\. Inclusion Criteria\n\nPatients must meet all of the following criteria to be eligible for inclusion in the study:\n\n1. The patient has fully understood the study and has voluntarily signed the informed consent form (ICF);\n2. Male or female patients aged 18 to 75 years, inclusive, at the time of signing the ICF;\n3. Imaging diagnosis consistent with stage T1 renal tumor, as assessed by MRI or CT;\n4. No definite collecting system invasion on preoperative MRI or CT assessment;\n5. The patient is scheduled to undergo partial nephrectomy (PN) or renal tumor enucleation after clinical evaluation by the physician and full discussion with the patient;\n6. Preoperative assessment indicates that main renal artery clamping with warm ischemia is planned;\n7. The surgery will be performed by a surgeon with experience in at least 50 cases of PN or renal tumor enucleation, and renal artery clamping will be performed using standardized vascular clamp application;\n8. Screening eGFR ≥30 mL\u002Fmin\u002F1.73 m², calculated using the CKD-EPI equation;\n9. No history of allergy or intolerance to UDCA or other bile acid preparations, and no UDCA contraindications or biliary tract-related diseases that, in the investigator's judgment, would make the patient unsuitable for UDCA treatment;\n10. The subject is willing and able to comply with the scheduled visits, treatment, laboratory tests, and other study-related procedures required by the protocol.\n\n2\\. Exclusion Criteria\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n1. Emergency surgery, defined as surgery required for medical reasons within 24 hours;\n2. Patients who are considered preoperatively to have a significant risk of bleeding, or whose surgery is expected to require complex renal reconstruction, and who are judged by the investigator to be unsuitable for participation in this study;\n3. Patients for whom non-standard ischemia techniques, such as selective\u002Fsegmental arterial clamping or zero-ischemia techniques, are planned preoperatively;\n4. Patients with a history of renal surgery on either kidney or previous kidney transplantation;\n5. Solitary kidney;\n6. History of major abdominal organ surgery within 1 year before surgery, which, in the investigator's judgment, may affect the conduct of the current surgery, safety assessment, or evaluation of study endpoints;\n7. Active lesions or clinically significant imaging abnormalities in either kidney that may substantially affect renal function assessment or perioperative AKI risk evaluation, including but not limited to renal artery stenosis, polycystic kidney disease, chronic pyelonephritis, severe hydronephrosis, or renal atrophy;\n8. Use of UDCA, chenodeoxycholic acid, bile acid sequestrants, or other drugs that may significantly affect bile acid metabolism within 1 month before screening;\n9. Continuous or systemic use of nephrotoxic drugs for more than 1 week within 3 months before screening, including but not limited to nonsteroidal anti-inflammatory drugs and aminoglycoside antibiotics;\n10. Continuous or systemic use of drugs that may significantly affect the gut microbiota or bile acid metabolism within 1 month before screening, including antibiotics, probiotics, high-dose glucocorticoids, immunosuppressants, potent laxatives, or antidiarrheal agents;\n11. Participation in another interventional clinical study within 3 months before screening, or ongoing treatment with another investigational drug or device;\n12. Uncontrolled active infection during the screening period, including but not limited to urinary tract infection, pulmonary infection, intra-abdominal infection, or systemic infection;\n13. Uncontrolled blood pressure abnormalities during the screening period, including mean seated SBP ≥180 mmHg or DBP ≥110 mmHg; symptomatic hypotension, SBP \\\u003C90 mmHg, or hypovolemia as judged by the investigator;\n14. History of New York Heart Association (NYHA) class III-IV heart failure, or hospitalization due to heart failure\u002Ffluid retention within 6 months before screening;\n15. Hepatic impairment, defined as meeting any of the following criteria: history of hepatic encephalopathy, history of esophagogastric varices, history of portocaval shunt surgery, Child-Pugh class C hepatic impairment, ALT or AST \\>3 × ULN, or total bilirubin \\>2 × ULN during the screening period;\n16. Diseases or surgical history that may significantly affect the absorption, distribution, metabolism, or excretion of the study drug, including but not limited to:\n\n1\\. history of active inflammatory bowel disease within the previous 6 months; 2. history of major gastrointestinal surgery, such as gastrectomy, gastrointestinal anastomosis, or bowel resection; 3. history of gastrointestinal ulcer and\u002For gastrointestinal or rectal bleeding within the previous 6 months; 4. history of pancreatic injury or pancreatitis within the previous 6 months; (17) Pregnant or breastfeeding women; (18) Women of childbearing potential who have a positive pregnancy test during the screening period, or who are unwilling to use effective contraception during the study; (19) Patients with a history of other malignancies are excluded, except for malignancies confirmed to have been cured or in remission for ≥5 years, radically resected basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ at any site； (20) Any other severe or uncontrolled medical disease, psychiatric disorder, or laboratory abnormality that may increase the risk associated with study participation, affect subject compliance, or interfere with the interpretation of study results, including but not limited to organ failure, active or uncontrolled immunodeficiency disease, active or uncontrolled HBV\u002FHCV\u002FHIV infection, cognitive impairment, or severe psychiatric disorder.","ALL","18 Years","75 Years",{"count":22,"type":23},146,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to learn if ursodeoxycholic acid, also called UDCA, can help protect kidney function in adults undergoing partial nephrectomy for kidney tumors. It will also learn about the safety of UDCA when used around the time of surgery.\n\nBefore the randomized part of the study begins, the first 6 participants will receive UDCA in a safety run-in phase. These participants will be closely monitored for side effects, laboratory abnormalities, and other medical problems to assess the preliminary safety and tolerability of perioperative UDCA administration. If no unacceptable safety concerns are identified, the study will proceed to the randomized, placebo-controlled phase.\n\nThe main questions this study aims to answer are:\n\n1. Is perioperative UDCA administration safe in patients undergoing surgery for renal tumors?\n2. Does UDCA lower the risk of acute kidney injury within 48 hours after partial nephrectomy?\n3. Does UDCA reduce the decline in kidney function after surgery?\n4. Does UDCA increase blood levels of UDCA and related bile acids during the perioperative period?\n5. What medical problems do participants have when taking UDCA around the time of surgery?\n6. Researchers will also evaluate whether UDCA affects urinary biomarkers of kidney injury.\n\nResearchers will compare UDCA with a placebo, a look-alike substance that contains no active drug, to see if UDCA can help protect the kidney from ischemia-reperfusion injury during partial nephrectomy.\n\nParticipants will:\n\n1. Take UDCA or a placebo three times a day from 2 days before surgery until 5 days after surgery.\n2. Undergo partial nephrectomy as planned by their treating surgeon.\n3. Have blood tests before and after surgery to check kidney function, liver function, and bile acid levels.\n4. Participants will provide urine samples before and after surgery for the assessment of kidney injury biomarkers.\n5. Be monitored for side effects, surgical complications, and other medical problems during hospitalization and follow-up.",[29],"Kidney Cancer",[31,32,33,34,35],"ursodeoxycholic acid","Ischemia-reperfusion injury","Acute kidney injury","perioperative","partial nephrectomy","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":23},"2027-12",{"name":46,"class":47},"Jinling Hospital, China","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100641105","phase-2-cd70-targeted-immuno-petct-directed-free-of-therapy-used-for-mccrcc-patients-with-imdc-favorable-or-intermediate-risk-100641105","NCT07615348","CD70-Targeted Immuno-PET\u002FCT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk","A Phase II Trial of CD70-Targeted Immuno-PET\u002FCT-Directed Treatment Holiday for Metastatic Clear Cell Renal Cell Carcinoma With IMDC Favorable or Intermediate Risk","PERFUMER-70","Inclusion Criteria:\n\nSTEP0: At Treatment Initiation\n\n1. Male or female subjects aged ≥ 18 years\n2. Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC (American Joint Committee on Cancer \\[AJCC\\] Stage IV)\n3. Histologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype\n4. Favorable or intermediate risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n5. Karnofsky Performance Status (KPS) grade ≥ 70%\n6. At least one measurable lesion on CT per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n7. At least one high-uptake target lesion on CD70-targeted immuno-PET\u002FCT per Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) version 1.0\n8. If CD70-negative lesions (visible on CT but lacking CD70 avidity on PET\u002FCT) are present at baseline, they must meet ALL the following conditions: cannot be target lesions, cannot be located in major involved organs, must be ≤ 3 in number, and must account for ≤ 30% of the total tumor burden\n9. Adequate organ and bone marrow function meeting all laboratory criteria:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; Hemoglobin ≥90 g\u002FL\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × upper limit of normal(ULN) (or ≤ 5 × ULN if hepatic metastases are present). Total bilirubin ≤ 1.5 × ULN (≤ 3 mg\u002FdL if Gilbert's syndrome)\n   * Serum creatinine ≤ 2.0 × ULN or estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin using the Cockcroft-Gault formula\n10. Capacity to comprehend and comply with protocol requirements, with documented informed consent signed\n11. Contraception agreement for sexually active fertile participants and partners to use medically accepted methods during the study and continue for 5 months after last treatment\n12. Negative pregnancy status at screening for women of childbearing potential\n\nSTEP1: At 12-Month Evaluation\n\n1. Patient met all eligibility criteria outlined above\n2. Patient must receive 12 months (±1m) of first line PD-1\u002FPD-L1 ICI + VEGFR-TKI therapy, without permanent discontinuation of both agents due to unmanageable toxicity\n3. Patient must have completed an CD70-targeted immuno-PET\u002FCT scan at 12m (±1m) from start of initial therapy\n4. Patients must meet one of the following criteria:\n\n   * Eligible for treatment discontinuation: For CD70-Positive Lesions: Sustained Disease Control (Complete Response \\[CR\\], Partial Response \\[PR\\], or Stable Disease \\[SD\\]) on CT for ≥ 12 weeks per RECIST 1.1, AND achieved Complete Metabolic Response (CMR) or Partial Metabolic Response (PMR) on CD70 immuno-PET\u002FCT per PERCIST 1.0 criteria; For CD70-Negative Lesions (If present at baseline): Must achieve a deep anatomical response, defined as Complete Response (CR) or Partial Response (PR) on CT, maintained for ≥ 12 weeks per RECIST 1.1\n   * Treatment continuation: not meeting criteria above\n\nExclusion Criteria:\n\nSTEP0: At Treatment Initiation\n\n1. Prior systemic therapy for advanced RCC\n2. Poor risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n3. Karnofsky Performance Status (KPS) \\\u003C70%\n4. Inadequate organ and bone marrow function\n5. Active brain metastases or leptomeningeal disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) who are clinically stable without progression prior to treatment\n6. Concurrent or prior invasive malignancies within the past 5 years, except adequately treated in situ\u002Fsuperficial cancers (e.g., non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix\u002Fbreast)\n7. Presence of uncontrolled major comorbidities or recent severe illnesses within 6 months, including but not limited to: uncontrolled hypertension, clinically significant cardiovascular disease, GI disorders with high risk of perforation\u002Ffistula, significant hematuria, hematemesis, hemoptysis, major bleeding history, severe active infections (including active HIV, HBV, or HCV), or severe autoimmune diseases (e.g., systemic lupus erythematosus, immune pneumonitis)\n8. Life expectancy \\\u003C 6 months\n9. Known allergy or hypersensitivity to the CD70 imaging agent or any of its excipients\n10. Severe hepatic or renal insufficiency, or inability to tolerate PET\u002FCT examination\n11. Medical\u002Fpsychiatric\u002Fsocial conditions compromising protocol compliance\n12. Pregnancy, lactation, or refusal of contraception during and for 5 months post-treatment\n\nSTEP1: At 12-Month Evaluation\n\n1. Failure to complete 12 months(±1m) of first-line PD-1\u002FPD-L1 + VEGFR-TKI therapy due to unmanageable toxicity or disease progression\n2. Failure or inability to undergo CD70-targeted immuno-PET\u002FCT scan at the 12-month evaluation timepoint\n3. Unacceptable clinical deterioration or investigator discretion indicating that a treatment holiday is not in the best interest of the patient",{"count":58,"type":23},75,[26],"The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET\u002FCT in patients with metastatic clear cell renal cell carcinoma (mccRCC). Specifically, the study aims to assess whether patients who achieve both anatomical disease control and metabolic response after 12 months of first-line PD-1\u002FPD-L1 ICI + VEGFR-TKI combination therapy can safely pause their treatment, improve quality of life without compromising therapeutic efficacy.",[62],"Metastatic Clear Cell Renal Cell Carcinoma",[62,64,65],"CD70-Targeted Immuno-PET\u002FCT","Treatment Holiday","2026-06-16",{"date":68,"type":40},"2026-06-18",{"date":66,"type":40},{"date":71,"type":23},"2029-08-10",{"name":46,"class":47},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100640556","phase-4-gastric-feeding-for-the-prevention-of-stroke-associated-pneumonia-100640556","NCT07630090","Gastric Feeding for the Prevention of Stroke-Associated Pneumonia","Comparing Early Post-pyloric Feeding Versus Gastric Feeding for the Prevention of Stroke-Associated Pneumonia in Patients With Severe Ischemic Stroke","FEED-SAP","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of severe ischemic stroke, with NIHSS score \\> 16 \\[15-16\\]\n* Confirmed dysphagia via swallowing assessment (Kubota Water Swallowing Test ≥ grade 3, or confirmed aspiration risk by FEES\u002FVFSS)\n* Time from onset to enrollment ≤ 72 hours\n* Expected survival ≥ 7 days\n* Non-mechanically ventilated patients\n* Signed informed consent from patient or legal representative.\n\nExclusion Criteria:\n\n* Diagnosed with pneumonia upon admission\n* High risk of gastrointestinal bleeding or perforation\n* Intestinal obstruction or gastrointestinal obstruction\n* Severe liver or kidney dysfunction\n* Advanced malignant tumor\n* Pregnancy or breastfeeding\n* Refusal to participate in the study",{"count":82,"type":23},174,[84],"PHASE4","This randomized controlled trial aims to compare the effectiveness of early post-pyloric feeding versus gastric feeding in preventing SAP in patients with severe ischemic stroke. The main question to answer is whether post-pyloric feeding group is better than the gastric feeding group for preventing SAP.",[87],"Stroke",[89,90,91,92,93],"Gastric Feeding","NIHSS","severe stroke","Post-Pyloric Feeding","stroke-associated pneumonia","NOT_YET_RECRUITING",{"date":96,"type":40},"2026-06-05",{"date":98,"type":23},"2026-06-15",{"date":100,"type":23},"2027-09-15",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":24,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100615794","effect-of-glp-1-on-intestinal-barrier-function-in-sbs-if-patients-a-preliminary-exploration-100615794","NCT07297238","Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants voluntarily provided written informed consent for this trial;\n* Aged 18 to 80 years, inclusive, regardless of gender;\n* With stable vital signs;\n* Diagnosis of SBS-IF, confirmed by existing medical\u002Fsurgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\\\u003C200 cm from the duodenojejunal flexure), and meeting one of the following criteria:\n\n  * Colon continuity maintained without jejunal\u002Fileal stoma (Type II or III);\n\n    * Presence of a jejunostomy or ileostomy (Type I);\n* Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;\n* Ability to comply with the medication dosing and visit schedule;\n* Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;\n* No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;\n* No history of drug abuse;\n* Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);\n* No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator;\n* Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;\n* History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;\n* Patients with malignancy at any site;\n* Those with psychiatric disorders, inability to cooperate, or impaired consciousness;\n* Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);\n* Immunodeficiency, or current use of immunosuppressants or corticosteroids;\n* Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;\n* Any other condition considered by the investigator as grounds for exclusion.","80 Years",{"count":111,"type":23},20,[113],"NA","Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.",[116,117],"Short Bowel Syndrome (SBS)","Intestinal Failure",[119,120,121,122],"GLP-1","short bowel syndrome","intestinal failure","Intestinal Barrier Function","2026-05-27",{"date":125,"type":40},"2026-05-28",{"date":127,"type":40},"2026-01-24",{"date":129,"type":23},"2026-06-30",{"name":46,"class":47},2,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":48},"100637359","a-study-on-the-efficacy-of-sodium-propionate-combined-with-anti-pd-1-immunotherapy-in-gastric-cancer-100637359","NCT07615907","A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer","Sodium Propionate Combined With Anti-PD-1 Immunotherapy on Tumor Efficacy in Gastric Cancer Patients","PAPGC","Inclusion Criteria:\n\n* Subjects voluntarily participated in the trial and signed the informed consent form;\n* Aged ≥ 18 years and \\\u003C 80 years, regardless of gender;\n* Stable vital signs;\n* Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;\n* Tumors judged as unresectable by attending physicians;\n* Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;\n* No history of allergic diseases and non-allergic constitution;\n* No history of drug abuse;\n* Non-pregnant and non-lactating females (applicable to male subjects as well);\n* No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;\n* Concurrent primary malignant tumors at other sites;\n* Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;\n* Patients with mental disorders, consciousness disturbance, or poor treatment compliance;\n* Suspected or confirmed history of drug abuse;\n* Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;\n* Pregnant or lactating women;\n* Sponsors, investigators directly involved in this trial, and their immediate family members;\n* Individuals unsuitable for enrollment for any reason as judged by the investigator.",{"count":111,"type":23},[113],"Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.",[144],"Gastric Cancer (GC)",[146,147,148],"Gastric cancer","Sodium propionate","Immunotherapy","2026-05-25",{"date":151,"type":40},"2026-05-29",{"date":153,"type":23},"2026-05-30",{"date":155,"type":23},"2027-08-30",{"name":46,"class":47},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":48},"100638072","phase-2-gut-microbiota-modulation-for-immunotherapy-resensitization-in-advanced-renal-cell-carcinoma-100638072","NCT07611825","Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma","REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study","REMEDY-RCC","Inclusion Criteria:\n\n* Pathological Diagnosis and Subtype Specification Histologically confirmed metastatic renal cell carcinoma (mRCC) of either clear cell type or non-clear cell type, with non-clear cell histologies restricted to papillary, chromophobe, or unclassified subtypes. Sarcomatoid features are allowed. Other non-clear cell subtypes, including but not limited to collecting duct carcinoma and renal medullary carcinoma, are excluded.\n\nBased on the pathological subtype, enrolled patients will be assigned to two cohorts: the primary cohort consists of patients with histologically confirmed metastatic clear cell RCC, and the exploratory cohort consists of those with histologically confirmed metastatic non-clear cell RCC (subtypes limited to papillary, chromophobe, or unclassified).\n\n* Immunotherapy Resistance Patients must have received at least two cycles of PD-1\u002FPD-L1 ICI therapy and demonstrated disease progression either during treatment or within six months after the last dose. Progressive disease must be confirmed by the investigator according to RECIST 1.1 criteria, with additional radiographic confirmation performed within four weeks after the initial documented progression.\n* Prior Treatment Lines and Sequence Restriction Patients must have received no more than two prior lines of systemic therapy, with no more than one line consisting of a PD-1\u002FPD-L1 ICI. This PD-1\u002FPD-L1 ICI based therapy may have been administered as first-line or second-line treatment for advanced or metastatic RCC, or as neoadjuvant or adjuvant therapy. Furthermore, this line of therapy must be the most recent prior treatment line, meaning that no other anticancer therapy has been administered following its completion.\n* Lesion Requirement Patients must have at least one measurable lesion per RECIST v1.1, as assessed by the investigator or by local radiologic evaluation.\n* Pre-treatment Tumor Biopsy Quality The pre-treatment tumor biopsy specimen must contain viable tumor tissue accounting for at least 75% of the total examined area.\n* Prior Radiotherapy Washout Participants who have received palliative radiotherapy for non-central nervous system lesions must complete such therapy at least 2 weeks prior to the first dose of study treatment. Participants for whom the only measurable lesions reside within a previously irradiated field are eligible for enrollment, provided that such lesions have shown clear progression and remain accurately measurable.\n* Recovery from Prior Treatment Toxicity All toxicities from prior anticancer therapies must have recovered to baseline or to Grade ≤1 according to the CTCAE version 5.0, with the exception of controllable AEs such as hypothyroidism that are clinically insignificant or remain stable under supportive care.\n* General Baseline Status Patients must be ≥18 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2, an American Society of Anesthesiologists (ASA) score ≤2, and a life expectancy ≥6 months.\n* Adequate Liver Function Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤3 × upper limit of normal (ULN), or ≤5 × ULN in patients with liver metastases. Total bilirubin ≤1.5 × ULN, except for patients with Gilbert's syndrome, in whom bilirubin ≤3.0 mg\u002FdL is allowed.\n* Adequate Renal Function Creatinine clearance ≥30 mL\u002Fmin (Cockcroft-Gault formula) or serum creatinine ≤1.5 × ULN, and urine protein-to-creatinine ratio ≤1 mg\u002Fmg.\n* Adequate Bone Marrow Function White blood cell count \\>2.0 × 10⁹\u002FL, absolute neutrophil count \\>1.5 × 10⁹\u002FL, platelet count \\>100 × 10⁹\u002FL, lymphocyte count ≥0.3 × 10⁹\u002FL, and hemoglobin ≥90 g\u002FL, with no blood transfusion within 14 days prior to assessment.\n* Viral Serology Patients must be negative for human immunodeficiency virus (HIV), negative for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with negative HBV DNA, and negative for hepatitis C antibody (HCV Ab), or positive with negative HCV RNA.\n* Informed Consent Patients must provide written informed consent.\n* Compliance Patients must be willing and able to adhere to the study protocol.\n\nExclusion Criteria:\n\n\\- Recent Microbiota Interference Patients are excluded if they have received systemic antibiotics within 4 weeks prior to screening, or have received any live bacterial preparations or commercial prebiotics within 2 weeks prior to screening, or are currently using or plan to use probiotics, yogurt, or foods supplemented with bacteria during the treatment period.\n\n\\- Immune-Related Severe Toxicity or Autoimmune Status\n\nPatients are excluded if they meet any of the following criteria:\n\n* Have a history of permanent discontinuation of immunotherapy due to immune-mediated adverse events;\n\n  * Have active or known autoimmune disease, except for type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and vitiligo;\n\n    * Have an immunosuppressive status, defined as confirmed immunodeficiency, receipt of systemic corticosteroids at a dose equivalent to \\>10 mg of prednisone per day or other immunosuppressive agents (excluding inhaled or topical corticosteroids), or a history of active autoimmune disease requiring systemic therapy within the past 2 years.\n\n      \\- Prior Specific Immunotherapy or Excessive Therapy Patients are excluded if they have received prior treatment with a CTLA-4 ICI or more than two prior systemic therapy regimens.\n\n      \\- Gastrointestinal Risk Factors Patients are excluded if they have a history of inflammatory bowel disease (including Crohn's disease or ulcerative colitis); chronic severe diarrhea; or grade ≥3 immune-related colitis; or present with gastrointestinal metastatic lesions; or have undergone major abdominal surgery that may impair intestinal absorption or peristaltic function.\n\n      \\- Oral Administration Barrier Patients are excluded if they have dysphagia or are unable to take the required oral study medication.\n\n      \\- Rapid Tumor Progression Patients are excluded if they have rapidly progressive disease such that, in the opinion of the investigator, they cannot safely tolerate a 4-week washout period and a 2-week reconditioning period.\n\n      \\- Active Interstitial Lung Disease or Pneumonitis Patients with active interstitial lung disease or pneumonitis, or a history of either condition requiring systemic steroid therapy, are excluded.\n\n      \\- Uncontrolled Brain Metastases or Central Nervous System Disease Patients with known brain metastases, cranial epidural disease, or significant vasogenic edema are excluded unless they have received adequate radiotherapy or surgery and have been stable for at least 4 weeks prior to the first dose of study treatment.\n\n      \\- Severe Cardiac Disease Patients are excluded if they have a history of myocarditis or congestive heart failure (New York Heart Association \\[NYHA\\] class III-IV), unstable angina, uncontrolled severe arrhythmia, or myocardial infarction within 6 months prior to enrollment.\n\n      \\- Recent Other Antineoplastic Treatment Patients are excluded if they have received, prior to the first dose of study treatment:any small molecule kinase inhibitor within 2 weeks; cytotoxic agents, biologics, or other systemic anticancer therapies within 4 weeks; radiotherapy for bone metastases within 2 weeks, or any other radiotherapy within 4 weeks.\n      * Planned Other Antineoplastic Treatment Patients are excluded if they require any other systemic or local antineoplastic therapy during the study period, with the exception of bisphosphonates or denosumab for the management of bone metastases.\n      * Active Second Malignancy Patients are excluded if they have a second active malignancy diagnosed within the preceding 2 years, with the exception of indolent or early-stage tumors, including non-melanoma skin cancer and carcinoma in situ.\n      * Laboratory Abnormalities\n\nPatients are excluded if they meet any of the following criteria:\n\n* White blood cell count \\\u003C2.0 × 10⁹\u002FL, absolute neutrophil count \\\u003C1.5 × 10⁹\u002FL, or platelet count \\\u003C100 × 10⁹\u002FL;\n\n  * AST\u002FALT \\>3 × ULN, or \\>5 × ULN in patients with liver metastases, or total bilirubin \\>1.5 × ULN (except for Gilbert's syndrome); ③Creatinine clearance \\\u003C30 mL\u002Fmin or serum creatinine \\>1.5 × ULN.\n\n    * Other Uncontrolled Comorbidities\n\nPatients are excluded if they have any of the following:\n\n* Uncontrolled tumor-related pain, with painful lesions requiring palliative radiotherapy to be managed prior to enrollment;\n\n  * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage more frequently than once per month, the presence of an indwelling catheter such as a PleurX® device is permitted; ③Moderate to severe hepatic impairment, defined as Child-Pugh class B or C; ④Uncontrolled or symptomatic hypercalcemia.\n\n    * Other General Exclusions\n\nPatients are excluded if they meet any of the following criteria:\n\n* Have received prior allogeneic stem cell transplantation or solid organ transplantation;\n\n  * Have active hepatitis B (HBV DNA positive), active hepatitis C (HCV RNA positive), or HIV infection;\n\n    * Have undergone major surgery within 4 weeks prior to study treatment;\n\n      * Have a history of allergy to food or antibiotics; ⑤Are pregnant, breastfeeding, or plan to conceive or father children during the study period (from pre-screening or screening visit until 120 days after the last dose); ⑥Require dialysis, have malabsorption syndrome, uncontrolled electrolyte disturbances, or require specific anticoagulants such as warfarin; ⑦Have any medical or psychological condition that may compromise safety or compliance.","90 Years",{"count":167,"type":23},33,[26],"The combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) has significantly improved clinical outcomes in patients with advanced renal cell carcinoma (RCC). However, 40%-60% of patients still develop primary or acquired resistance. For those with resistant disease, current immune rechallenge strategies have yet to demonstrate clear clinical benefit. Emerging evidence indicates that the gut microbiota plays a critical role in modulating responses to immunotherapy. Microbiota-modulating approaches, including fecal microbiota transplantation (FMT) and live bacterial formulations such as CBM588, have shown preliminary potential to enhance sensitivity to immunotherapy and improve patient outcomes. Nevertheless, whether gut microbiota modulation can resensitize advanced RCC to immunotherapy remains to be investigated.\n\nThe REMEDY-RCC trial is an investigator-initiated, prospective, open-label, phase II, parallel two-cohort exploratory study primarily designed to investigate whether gut microbiota modulation can restore sensitivity to immunotherapy in patients with advanced RCC. Given the substantial differences in the tumor immune microenvironment and response to ICIs between clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC), this study employs a parallel two-cohort design to stratify these two patient populations: a primary cohort consisting of patients with metastatic ccRCC, and an exploratory cohort consisting of patients with metastatic nccRCC. The primary and secondary endpoints will be analyzed in the primary cohort, whereas the exploratory cohort will be used solely for exploratory and descriptive analyses. The study plans to enroll approximately 33 adult patients with advanced or metastatic RCC, including 27 with metastatic ccRCC and 6 with metastatic nccRCC. Eligible patients will receive the following sequential interventions: bowel decontamination with amoxicillin-clavulanate potassium followed by polyethylene glycol (PEG) solution, high-dose gut colonization and maintenance supplementation with live Clostridium butyricum powder combined with soluble dietary fiber, and immune rechallenge therapy consisting of a PD-1 immune checkpoint inhibitor (ICI) combined with four cycles of a CTLA-4 ICI, followed by maintenance therapy with the PD-1 ICI alone. Treatment will continue until disease progression, unacceptable toxicity, completion of the planned treatment cycles, or withdrawal of consent.\n\nThe REMEDY-RCC trial requires specific follow-up for enrolled patients. Radiological response is assessed longitudinally using computed tomography (CT). Tissue and body fluid samples collected from patients will be used for biomarker and multi-omic analyses.\n\nThe primary endpoint of the trial is the objective response rate (ORR) in the primary cohort, as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Sample size for the primary cohort was determined using Simon's optimal two-stage design, with a one-sided α of 0.10 and power (1-β) of 0.80. The unacceptable response rate (P0) was set at 17.4%, based on the ORR observed in the FRACTION-RCC study for nivolumab plus ipilimumab rechallenge in patients with metastatic ccRCC who had progressed after prior immunotherapy. The target response rate (P1) was established considering that FMT has been shown to increase ORR by approximately 20% in immunotherapy-resistant melanoma. Given that metastatic RCC and melanoma are both considered immunologically responsive tumor types, a comparable therapeutic benefit from gut microbiota remodeling is anticipated. Accordingly, P1 was set at 37.4%. This effect size is clinically meaningful and would be non-inferior to the clinical efficacy of cabozantinib in metastatic RCC that has progressed following immunotherapy.\n\nThe primary cohort will initially enroll six patients for safety assessment. If the treatment is deemed safe, further accrual will follow Simon's two-stage design, and enrollment of the exploratory cohort will be considered. After these six patients, an additional six patients will be enrolled, bringing the total to 12, at which point an interim analysis will be performed. If the number of objective responses at the interim analysis is ≤ 2, the trial will be terminated early. If ≥3 objective responses are observed, an additional 12 patients will be enrolled, resulting in a total sample size of 24 patients. Accounting for a potential 10% dropout rate, the study plans to enroll 27 patients in total.\n\nThe exploratory cohort is planned to enroll no more than 6 patients (not exceeding 20% of the total enrollment), with a fixed-sample descriptive design. The sample size calculation is not based on statistical hypothesis testing, and all efficacy endpoints will be reported using descriptive statistics. The total planned sample size is 33 patients, comprising 27 patients in the primary cohort and 6 patients in the exploratory cohort.",[171],"Advanced RCC",[173,174,148,175],"Gut Microbiota Modulation","Advanced Renal Cell Carcinoma","Resensitization","2026-05-20",{"date":125,"type":40},{"date":42,"type":23},{"date":180,"type":23},"2028-12-31",{"name":46,"class":47},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":48},"100636889","phase-2-perioperative-trial-with-iotki-for-multi-stage-clear-cell-renal-cell-carcinoma-100636889","NCT07571551","Perioperative Trial With IO\u002FTKI for Multi-stage Clear Cell Renal Cell Carcinoma","A Prospective, Open-label, Phase II Clinical Trial of Perioperative Toripalimab Plus Lenvatinib for Multi-stage Clear Cell Renal Cell Carcinoma (ccRCC)","TRIPLE-PATH","Inclusion Criteria:\n\n* Patients have fully understood and give written informed consent prior to receive neoadjuvant therapy. Patients with history of major psychiatric disease must be judged able to fully understand the trial, and the explicit consent of family members is required;\n* Patients with the ages range from 18 to 80 years old (at the time of signing informed consent);\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;\n* Patients have at least 1 measurable target lesion according to RECIST v1.1. The target lesion can be biopsied as per protocol.\n* Histologically confirmed clear cell RCC;\n* Patients will be enrolled into 3 separate cohorts based on their clinical TNM at the time of baseline screening:\n\n  1. Cohort 1: localized ccRCC (cT1-2N0M0): the primary tumor in this cohort must meet the subsequent criteria:\n\n     * The cT1a primary tumor should have ≥10 R.E.N.A.L. score, or locate in renal hilum close to renal artery or its main branch;\n\n       * Patients with cT1b-2b primary tumors can be directly enrolled;\n\n         * In case of necessary, patients will undergo dual radiological examinations using contrast-enhanced CT and MRI to rule out potential invasion of the renal pelvis or perirenal fat as per protocol.\n  2. Cohort 2: locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0);\n  3. Cohort 3: metastatic ccRCC (cTanyNanyM1): the patients should be evaluated as suitable for cytoreductive nephrectomy.\n\n     * Patient have no symptomatic metastatic lesions requiring urgent intervention;\n\n       * The sum of the diameters of the other target lesions (excluding the primary tumor) does not exceed the longest diameter of the primary tumor.\n* The patients who are treatment-naive, and have not received systemic therapy for any tumor;\n* Adequate main organ function. The screening laboratory indicators must meet the following criteria:\n\n  1. Hemoglobin ≥ 90 g\u002FL (Without blood transfusion);\n  2. Platelets count ≥ 100 x 109\u002FL;\n  3. Absolute neutrophil count ≥ 1.5 x 109\u002FL;\n  4. Serum creatinine ≤ 1.5 x ULN, or eGFR \\> 60 mL\u002Fmin\u002F1.73m2;\n  5. Total bilirubin ≤ 1.5 mg\u002FdL;\n  6. Aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) ≤ 2.5 x ULN for patients without evidence of liver metastases; AST and\u002For ALT ≤ 5 x ULN for patients with liver metastases;\n  7. Normal CK;\n  8. Normal Troponin T;\n  9. Normal LDH.\n* Willingness and ability to comply with planned visits, therapeutic laboratory testing, and other procedures.\n\nExclusion Criteria:\n\n* Signs of tumor metastasis involving the central nervous system, or radiological evidence of brain metastasis;\n* History of malignant tumors other than ccRCC within the previous 5 years, with the exception of malignant tumors that can be expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with radical surgery);\n* Prior to participating in the study, patients have received prior immune checkpoint inhibitors, investigational drugs or device therapy;\n* History of undergoing major surgery (judged by the investigator) within 4 weeks before the first trial dose, are recovering, or are unable to undergo baseline puncture;\n* History of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications to immunotherapy restart, including but not limited to:\n\n  1. Grade 2-4 immune myocarditis;\n  2. Severe grade 4 proteinuria;\n  3. Severe or life-threatening grade 4 immune hepatitis;\n  4. Severe grade 3-4 immune pneumonitis;\n  5. Severe inflammatory arthritis that significantly affects daily life or quality of life;\n  6. Severe neurological toxicity:\n  7. Myasthenia gravis grade 2-4;\n  8. Guillain-Barre syndrome (GBS) or transverse myelitis of any grade;\n  9. Grade 2-4 encephalitis;\n  10. Severe or life-threatening grade 3-4 pancreatitis;\n  11. Severe or life-threatening bullous disease (grade 3-4);\n  12. Severe grade 3-4 uveitis or episcleritis.\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or long-term corticosteroid therapy.\n* Non-resolution of toxicity after previous antineoplastic therapy, i.e., resolution to baseline, CTCAE v5.0 grade 0-1 (excluding alopecia), or inclusion\u002Fexclusion criteria. Irreversible toxicities (e.g., hearing loss) that would not reasonably be expected to be exacerbated by the study drug can be included in the study;\n* Known history of clinically significant liver disease, including active viral hepatitis (hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HbcAb) positive, HBV DNA\\>10000 copies \u002FmL or \\>2000 IU\u002FmL; Hepatitis C virus (HCV) antibody positive and HCV RNA positive), or other active hepatitis, clinically significant moderate to severe cirrhosis;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients who do not need drainage of effusion or stop drainage for 3 days without significant increase in effusion can be enrolled);\n* Receiving a systemic corticosteroid (prednisone \\> 10mg\u002F day or equivalent) or other immunosuppressive medication within 14 days before the first study medication;\n* Patients with any severe and\u002For uncontrolled disease, including:\n\n  1. Hypertension that is not well controlled by antihypertensive medication;\n  2. Unstable angina pectoris or myocardial infarction, coronary artery bypass grafting or stent implantation within 6 months before study medication;\n  3. Grade I or above myocardial ischemia or myocardial infarction, arrhythmia (including QTc≥480ms) and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); Degree II or above heart block; Left ventricular ejection fraction (LVEF) \\\u003C 50%;\n  4. Poorly controlled diabetes (fasting blood glucose \\> 10 mmol\u002FL);\n  5. Patients with urinary protein ≥++ and confirmed 24-hour urinary protein \\> 1.0g;\n  6. Severe active or uncontrolled infection.\n* Patients with or suspected to have active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* Renal failure requiring hemodialysis or peritoneal dialysis;\n* Patients with a history of immunodeficiency, including HIV positive patients, other acquired immunodeficiency diseases, congenital immunodeficiency diseases, or organ transplantation history;\n* History of live attenuated vaccine inoculation within 4 weeks before the first study drug or the expected vaccination during the study period;\n* History of psychiatric drug abuse and can not quit or have a history of mental disorders;\n* Women who are of childbearing potential. Women of childbearing potential must have a negative serum or urine pregnancy test, and must use appropriate methods of contraception.\n* The presence of any other severe, acute or chronic medical disease or mental illness or laboratory abnormality, as judged by the investigator, that may increase the risk associated with participation in the study or that may interfere with the interpretation of the results of the study.",{"count":58,"type":23},[26],"The IO\u002FTKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC. Currently, IO\u002FTKI regimens are serving as neoadjuvant treatment in arising clinical trials for ccRCC. Although anatomical change reflected by radiological response is reported in most neoadjuvant trials, only few studies focus on evaluation for pathological response in ccRCC.\n\nThe TRIPLE-PATH trial is an investigator initiated prospective, open-label phase II trial with the main objective to evaluate the clinical activity of preoperative\u002Fneoadjuvant therapy of toripalimab plus lenvatinib as mesured by pathological response of resected primary lesion in multi-stage ccRCC. Patients with ccRCC will be enrolled into 3 different cohorts based on their clinical TNM at the time of screening: localized ccRCC (cT1-2N0M0), locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0), and metastatic ccRCC (cTanyNanyM1). Toripalimab (240mg Q3W) will be administered intravenously on the 1st day, and lenvatinib (20mg QD) will be administered orally once daily of each 3 weeks cycle. Patients in all cohorts will receive 4 cycles of preopertive\u002Fneoadjuvant toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO), and a subsequent partial\u002Fradical nephrectomy 7-10 days after the last cycle. For adjuvant\u002Fpostoperative treatment, patients who undergo R0 resection presented with cT1-2aN0M0G4\u002FcT2bN0M0G3-4\u002FcT3-4N0M0Gany\u002FcTanyN1M0Gany will receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo simultaneous resection of all oligometastases considered as \"no evidence of disease\" (M1 NED) will also receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive postoperative doses of toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO) for 17 cycles.\n\nSpecific follow-up for the enrolled patients is required in the TRIPLE-PATH trial. Longitudinal CT\u002FMRI is utilized to assess the radiological response. Tissues and body fluid samples collected from the patients will be utilized for biomarker and multi-omic analysis.\n\nThe primary endpoint of the TRIPLE-PATH trial is major pathological response (MPR) in the primary lesion according to the pathological response reporting guidelines by the International Neoadjuvant Kidney Cancer Consortium (INKCC). Simon's two-stage minimax design is adopted by TRIPLE-PATH. An initial of 12 patients per cohort (36 in total) will be recruited, following an interim analysis. Recruitment to any cohort will be suspended if MPR is not observed in any patient at the interim analysis. If MPR is observed in at least 1 patient, additional 9 patients will be recruited in each cohort to at most 21 patients. Considering potential 15% dropout rate in each cohort, an anticipation of 25 patients will be recruited for each cohort (75 in total) in this study.",[194],"Clear Cell RCC",[196,148,197,198,199,200],"ccRCC","Tyrosine Kinase Inhibitors","pathologic response","Nephrectomy","Perioperative","2026-05-06",{"date":203,"type":40},"2026-05-11",{"date":201,"type":40},{"date":206,"type":23},"2032-12-31",{"name":46,"class":47},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":48},"100508679","radial-versus-femoral-access-for-thrombectomy-in-patients-with-acute-basilar-artery-occlusion-100508679","NCT05903560","Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion","Inclusion Criteria:\n\n1. Acute ischemic stroke in the posterior circulation confirmed by symptoms and imaging examinations.\n2. Basilar artery occlusion confirmed by computed tomographic angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).\n3. Age ≥ 18 years.\n4. Time from symptom onset to randomization within 24 hours of the estimated time of basilar artery occlusion.\n5. Baseline NIHSS score ≥ 10 before randomization.\n6. Intact dual circulation of the hand assessed by the modified Allen's test.\n7. Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Pre-stroke disability with mRS score ≥ 3.\n2. Pregnant or lactating women.\n3. Allergic to contrast agents or nitinol devices.\n4. Participation in other clinical trials.\n5. Systolic blood pressure \\> 185 mmHg or diastolic blood pressure \\> 110mmHg, and can not be controlled by antihypertensive drugs.\n6. Known genetic or acquired bleeding diathesis, lack of coagulation factors; or oral anticoagulant therapy with INR \\> 1.7.\n7. Baseline lab values: blood glucose \\\u003C 50mg\u002FdL (2.8mmol\u002FL) or \\> 400mg\u002FdL (22.2 mmol\u002FL), platelet count \\\u003C 50\\*109 \u002FL, or hematocrit \\\u003C 25%.\n8. Life expectancy less than 1 year.\n9. Lost to follow-up within 90 days (e.g. no fixed residence, overseas patients, etc.).\n10. Acute ischemic stroke within 48 hours after percutaneous coronary intervention, cerebrovascular intervention, or major surgery (patients can be included if more than 48 hours).\n11. Clinical manifestations of central nervous system vasculitis.\n12. Premorbid nervous system diseases or mental disorders hindering the assessment of the disease.\n13. Diseases or anatomical abnormalities that make it difficult for radial or femoral artery puncture, sheath insertion or instrument delivery, such as local infection, anatomical abnormalities confirmed by ultrasound or other imaging examinations, previous interventional or open surgery.",{"count":215,"type":23},386,[113],"Stroke is one of the most important diseases endangering the health and quality of life of Chinese people. Acute ischemic stroke (AIS) is commonly caused by cerebrovascular stenosis or occlusion. The most effective treatment for AIS is timely and successful angiographic reperfusion.\n\nDue to the large diameter and obvious positioning of bilateral femoral arteries, the transfemoral artery (TFA) using Seldinger's technique has been the most commonly used approach for endovascular treatment. However, recent studies have suggested that the radial artery is an ideal puncture site for cerebrovascular intervention. Small sample studies have confirmed that endovascular recanalization for acute anterior circulation large vessel occlusion via TRA has been safe and effective. Still, there are some complex approaches needed to be converted to TFA. There has been no difference in total operation duration and fluoroscopy time between TRA and TFA, but the TRA group had higher radiation dose and shorter hospital stays than the TFA group. In addition, TRA tends to be more convenient than TFA, especially for posterior circulation lesions.\n\nHowever, the current studies are based on a single center with a small sample size, and there has been still a lack of large-sample randomized controlled experiments to verify the safety and effectiveness of posterior endovascular recanalization via TRA.",[219],"Acute Ischemic Stroke","2026-04-28",{"date":222,"type":40},"2026-04-30",{"date":224,"type":40},"2023-07-22",{"date":226,"type":23},"2026-09",{"name":46,"class":47},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":48},"100611204","effect-of-remote-ischemic-preconditioning-on-early-neurological-deterioration-in-acute-perforating-artery-infarction-100611204","NCT07237542","Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction","Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction (RIC-END): A Randomised Multicentre Trial","RIC-END","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Diagnosed with acute ischemic stroke;\n3. Clinical symptoms consistent with perforating artery infarction (NIHSS score ≤5, with consciousness item 1a ≤1);\n4. Time from onset to randomization within 48 hours;\n5. Diffusion-weighted imaging (DWI) showing a single infarct in the perforating artery territory with a maximum diameter ≤30 mm, meeting at least one of the following:\n\n(1) Diameter ≤15 mm and involving two or more axial slices; (2) Maximum diameter ≥15 mm; (3) Connected to the ventral surface of the pons but not crossing the midline; 6) Stenosis of parent artery \\\u003C70%; 7) Signed informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Received intravenous thrombolysis or endovascular treatment prior to randomization;\n2. Secondary stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other conditions;\n3. History of intracranial hemorrhage;\n4. Presence of RIC contraindications, such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease;\n5. Uncontrolled severe hypertension (systolic blood pressure \\[BP\\] ≥180 mmHg or diastolic BP ≥110 mmHg);\n6. Severe hepatic or renal dysfunction (Alanine Aminotransferase or Aspartate Aminotransferase \\> 3 × upper limit of normal; creatine kinase \\>3 × upper limit of normal; estimated Glomerular Filtration Rate \\\u003C 30 mL \u002F min \u002F 1.73 m²);\n7. Patients with thrombocytopenic purpura, coagulation disorders, or active visceral bleeding;\n8. Patients in the acute phase of fundus hemorrhage;\n9. History of severe aphasia or psychiatric disorders affecting clinical assessment;\n10. Life expectancy \\\u003C90 days;\n11. Pregnancy;\n12. Inability to comply with follow-up;\n13. Participation in other clinical trials.",{"count":237,"type":23},910,[113],"This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).",[241,242],"Ischemic Stroke","Remote Ischaemic Preconditioning",[244,245,246,247],"perforating artery stroke","remote ischemic preconditioning","early neurological deterioration","randomized controlled trial","2026-01-30",{"date":250,"type":40},"2026-02-03",{"date":252,"type":40},"2025-12-11",{"date":254,"type":23},"2027-11-20",{"name":46,"class":47},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":263,"targetDuration":265,"studyType":266,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":48},"100615611","contrast-enhanced-ultrasound-and-super-resolution-imaging-predict-renal-function-outcome-after-nephrectomy-100615611","NCT07294859","Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy","A Prospective Clinical Study on the Predictive Value of CEUS and Super-resolution Imaging Technology for Renal Function Outcome in Patients After Partial or Radical Nephrectomy","Inclusion Criteria:\n\n* Fully understood and voluntarily signed the informed Consent Form (ICF);\n* Age: \\> 18 (at the time of signing the informed consent form); Gender is not limited.\n* Preoperative eGFR \\> 45ml\u002Fmin\u002F1.73m2 (corrected CKD-EPI formula);\n* After the clinician formulates the treatment plan and communicates with the patient, they decide whether to perform radical nephrectomy or partial nephrectomy.\n* ECOG score: 0-2 points;\n* Be willing and able to abide by the visits, treatments, laboratory tests and other procedures of the research plan.\n\nExclusion Criteria:\n\n* Patients with solitary kidney or severe contralateral renal insufficiency (eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2);\n* Preoperative reliance on renal replacement therapy (such as dialysis, etc.);\n* Those who fail to complete the nephrectomy as planned during the operation;\n* Patients with lymph node metastasis, distant metastasis or venous tumor thrombus;\n* The healthy kidney has undergone radiotherapy, ablation or other surgeries.\n* Have a history of allergy to ultrasound contrast agents;\n* Have any contraindications for contrast-enhanced ultrasound, such as right-to-left shunt, severe pulmonary hypertension, etc.\n* Patients with hemodynamic instability, including those with persistent hypotension (blood pressure \\\u003C 90\u002F60 MMHG), uncontrollable heart failure, active bleeding (such as gastrointestinal and cerebral hemorrhage, etc.), or those with a bleeding tendency and hemoglobin \\\u003C 60g\u002FL and\u002For platelet count \\\u003C 50×109\u002FL;\n* Accompanied by structural abnormalities of the urinary system or functional abnormalities that cannot be corrected in a short time (such as duplicate kidneys, polycystic kidneys, horseshoe kidneys, isolated kidneys, renal artery stenosis \\> 50%, urinary tract obstruction, and previous history of kidney surgery, etc.), long-term indwelling of urinary catheters, etc.\n* There are other diseases that limit life expectancy to less than six months;\n* Previous (≤30 days before randomization) or concurrent participation in another clinical study.",{"count":264,"type":23},285,"12 Months","OBSERVATIONAL","The goal of this prospective cohort study is to evaluate the predictive value of Contrast-Enhanced Ultrasound (CEUS) and Super-Resolution Imaging (SRI) technologies regarding renal function outcomes in patients with renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. The main questions it aims to answer are:\n\nCan quantitative parameters of renal microcirculation and microvascular structure derived from CEUS and SRI predict long-term renal function (defined as New Baseline eGFR for radical nephrectomy and Recovery from Ischemia for partial nephrectomy)? Can these imaging parameters accurately predict the occurrence, severity, and early recovery of postoperative acute kidney injury (AKI)? Researchers will monitor the dynamic evolution of renal blood flow and microvascular density by comparing the affected kidney to the contralateral healthy kidney before and after surgery to see if these biomarkers correlate with clinical outcomes.\n\nParticipants will:\n\nUndergo CEUS and SRI examinations before surgery and at specific time points after surgery (e.g., within 7 days) to visualize renal microvasculature.\n\nProvide blood and urine samples for standard laboratory tests (such as serum creatinine and Cystatin C) to assess kidney function during hospitalization.\n\nAttend follow-up visits at 1, 3, 6, 9, and 12 months post-surgery to monitor long-term renal recovery and complete necessary imaging assessments (CT or Ultrasound).",[199,269,270],"Renal Cell Cancer","AKI - Acute Kidney Injury","2025-12-08",{"date":273,"type":40},"2025-12-19",{"date":275,"type":40},"2025-09-01",{"date":277,"type":23},"2027-12-01",{"name":46,"class":47},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":24,"phases":288,"briefSummary":289,"conditions":290,"keywords":295,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":48},"100597781","kidney-protective-intervention-with-salt-substitute-after-kidney-tumor-surgery-100597781","NCT07062952","Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery","Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery: a Single-center Randomized Controlled Study(KISS Study)","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  1. Voluntary participation with signed informed consent from both the primary participant and all cohabiting family members, with commitment to study procedures and follow-up;\n  2. Age ≥18 years at enrollment (when signing informed consent), any gender;\n  3. Diagnosed kidney tumor patients who underwent radical nephrectomy or partial nephrectomy (no restrictions on surgical approach);\n  4. Preoperative eGFR \\>60 ml\u002Fmin\u002F1.73m² (calculated by CKD-EPI equation);\n  5. Serum potassium \\\u003C4.8 mmol\u002FL;\n  6. Predominantly home-based dietary habits (\\>90% meals prepared at home, assessed via self-report);\n  7. Normal contralateral renal function at screening;\n  8. Normal cardiopulmonary and hepatic function:\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following:\n\n  1. Participant or cohabiting family members currently using potassium-sparing diuretics or potassium supplements, or prior use of salt substitutes;\n  2. Post-discharge eGFR \\\u003C45 ml\u002Fmin\u002F1.73m² without significant fluctuation;\n  3. Comorbid chronic kidney diseases (e.g., diabetic nephropathy, lupus nephritis);\n  4. Preoperative history of urinary tract obstruction;\n  5. Cohabiting family member(s) with CKD (eGFR \\\u003C45 ml\u002Fmin\u002F1.73m²);\n  6. Planned postoperative nephrotoxic medications (e.g., anti-neoplastic agents, immunotherapy);\n  7. Uncontrolled diabetes (HbA1c ≥12%);\n  8. Uncontrolled hypertension (seated SBP ≥180 mmHg or DBP ≥110 mmHg), symptomatic hypotension (SBP \\\u003C90 mmHg), or clinically evident hypovolemia;\n  9. Preoperative proteinuria (≥1+ on dipstick);\n  10. Severe cardiovascular disease (NYHA Class III-IV), gastrointestinal obstruction, or hyperkalemia history;\n  11. BMI \\\u003C18.5 kg\u002Fm² or \\>30 kg\u002Fm²;\n  12. Participation in another clinical trial ≤30 days before randomization or concurrently;\n  13. Communication barriers or anticipated non-adherence;\n  14. Structural\u002Ffunctional urological abnormalities (e.g., duplicated kidneys, polycystic kidneys, renal artery stenosis, stones, BPH) or indwelling catheters;\n  15. Prior radiotherapy\u002Fablation\u002Fsurgery on the contralateral kidney;\n  16. Life expectancy \\\u003C6 months (e.g., metastatic renal carcinoma).",{"count":287,"type":23},200,[113],"This clinical trial is an open-label, randomized controlled study designed to evaluate the efficacyand safety of salt substitutes in protecting renal function after kidney tumor surgery, aiming toprovide dietary renal protection strategies for postoperative kidney tumor patients. lt will alsoassess the feasibility of salt substitute intervention. The primary research questions are:\n\n1. Does a salt substitute diet significantly improve estimated glomerular filtration rate (eGFR) compared to a regular salt diet in postoperative kidney tumor patients?\n2. What is the safety profile of salt substitute intervention in postoperative kidney tumor patients?\n3. What is the compliance rate among postoperative kidney tumor patients using saltsubstitutes?\n4. ls the salt substitute intervention feasible?\n\nResearchers will compare the intervention group (salt substitute diet) with the control group (regular salt diet) to determine whether salt substitutes effectively improve postoperative eGFR in kidney tumor patients.\n\nParticipants will be required to:\n\n1. Consume salt substitutes or regular salt daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.\n2. Undergo scheduled baseline assessments at 1, 3, 6, and 12 months post-surgery, with 24-hoururine tests at months 1 and 6 to evaluate compliance.\n3. Receive regular monitoring of blood electrolytes, eGFR, and other renal function indicators.\n4. Document any adverse events or health status changes during the study period.",[291,292,293,199,294],"Kidney Tumors","CKD","Salt Substitute","eGFR",[296,292,297,298,294,299,300,301,247,302,303],"kidney tumor","Salt substitute","nephrectomy","kidney protection","kidney function","open-label","Renal function compensation","CKD with clinical significance","2025-12-07",{"date":306,"type":40},"2025-12-15",{"date":308,"type":40},"2025-04-24",{"date":310,"type":23},"2027-12-31",{"name":46,"class":47},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":319,"targetDuration":321,"studyType":266,"phases":4,"briefSummary":322,"conditions":323,"keywords":336,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":48},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.",{"count":320,"type":23},39,"12 Weeks","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[324,325,326,327,328,329,330,331,332,333,269,334,335],"Neoplasms","Kidney Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Female Urogenital Diseases","Male Urogenital Diseases","Urogenital Diseases","Kidney Diseases","Urologic Diseases","Carcinoma","Carcinoma, Renal Cell","Antineoplastic Agents",[337,338,339],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":342,"type":40},"2025-12-05",{"date":344,"type":40},"2024-09-01",{"date":346,"type":23},"2026-09-01",{"name":46,"class":47},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":354,"targetDuration":356,"studyType":266,"phases":4,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":48},"100509720","renal-cancer-monitoring-based-on-ctdna-methylomics-a-prospective-cohort-study-memory-study-100509720","NCT05917106","Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)","Inclusion Criteria:\n\n* Newly diagnosed renal cell carcinoma\n* Without any treatment\n* Agree and accept radical surgical treatment\n* Signed written informed consent\n* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1\n* Follow up protocol and related procedures\n\nExclusion Criteria:\n\n* Had other cancers\n* Had received any antitumor therapy before\n* Known or suspected active autoimmune disease\n* Informed consent is not possible due to medical or psychiatric problems\n* Have clinical symptoms or diseases of the heart that are not well controlled\n* Patients judged by the investigators to be unsuitable for inclusion in this study",{"count":355,"type":23},450,"5 Years","To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.",[333,359,360,325,29],"Renal Cell Carcinoma","RCC",{"date":252,"type":40},{"date":363,"type":40},"2022-12-26",{"date":365,"type":23},"2030-06",{"name":46,"class":47},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":131},"100526818","phase-4-comparison-of-perioperative-conscious-sedation-during-endovascular-thrombectomy-in-acute-ischemic-stroke-100526818","NCT06139692","Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke","Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke (PEACE) A Randomised Multicentre Trial","PEACE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Presenting with symptoms of acute ischemic stroke\n3. CTA or MRA confirmed occlusion of the anterior circulation (intracranial carotid artery or M1, M2 segment of the middle cerebral artery)\n4. Randomization finished within 24 hours of symptom onset or time last know well\n5. Pre-stroke mRS score ≤2\n6. NIHSS score ≥6 at the time of randomization\n7. ASPECTS value ≥3\n8. Informed consent signed\n\nExclusion Criteria:\n\nGeneral exclusion criteria\n\n1. Pregnant or lactating women\n2. Known allergy to contrast agents or nitinol devices\n3. Known allergy to midazolam or other benzodiazepines\n4. Known allergy to dexmedetomidine or its components\n5. Planned to receive general anesthesia for EVT\n6. Uncontrolled hypertension or hypotension (defined as systolic blood pressure \\>185 mmHg or \\\u003C 90 mmHg, diastolic blood pressure \\>110 mmHg or \\\u003C 60 mmHg)\n7. Second-degree or third-degree heart blockage or bradyarrhythmia with a baseline heart rate lower than 50 beats\u002Fmin\n8. Any major surgery or serious trauma within 14 days\n9. Known genetic or acquired bleeding diathesis (platelet count \\\u003C 100\\\\\\*109 \u002FL, activated partial thromboplastin time \\> 50 s or international normalized ratio \\> 1.7)\n10. Blood glucose \\\u003C2.8 or \\> 22.2 mmol\u002FL\n11. Severe renal insufficiency (defined as glomerular filtration rate \\\u003C30 ml\u002Fmin or serum creatinine \\>220 mmol\u002FL (2.5mg\u002Fdl))\n12. Receiving hemodialysis or peritoneal dialysis\n13. Life expectancy less than 1 year\n14. Severe agitation or seizures\n15. Clinical manifestations of central nervous system vasculitis\n16. Premorbid neurological disease or mental disorders confounding evaluation\n17. Unwilling to be followed up within 90 days\n18. Participation in other interventional randomized clinical trials Imaging exclusion criteria\n\n1\\. Evidence of intracranial hemorrhage on CT or MRI 2. Cerebellar infarction with obvious space-occupying effects and fourth ventricle compression on CT or MRI 3. Any untreated or incompletely treated intracranial aneurysm or any intracranial vascular malformation 4. Bilateral occlusion or multiple intracranial vessels occlusions 5. Intracranial tumors (with mass effect)",{"count":376,"type":23},810,[84],"This study aims to conduct a multicenter, prospective, randomized clinical trial to scientifically evaluate the safety and efficacy of different perioperative sedation methods during endovascular thrombectomy in acute ischemic stroke patients with large vessel occlusion in the anterior circulation.",[219],"2025-11-16",{"date":382,"type":40},"2025-11-18",{"date":384,"type":40},"2023-11-21",{"date":386,"type":23},"2026-06-13",{"name":46,"class":47},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100610648","phase-2-sequential-transarterial-chemoembolization-tace-stereotactic-body-radiation-therapy-sbrt-and-immune-checkpoint-inhibitors-for-unresectable-hepatocellular-carcinoma-treated-with-donafenib-100610648","NCT07230314","Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib","Luminate Study: A Single-arm, Single-center, Open-label Clinical Study of Transarterial Chemoembolization (TACE) Plus Stereotactic Body Radiotherapy (SBRT) Combined With PD-1\u002FL1 Inhibitor and Donafenib as First-line Therapy for Unresectable Hepatocellular Carcinoma.","Inclusion Criteria:\n\n1. Age range from 18 to 75 years old (including 18 and 75), with no gender restrictions;\n2. Hepatocellular carcinoma diagnosed by histopathology, cytology or imaging;\n3. Has not received any systemic anti-tumor therapy for the current stage of the disease in the past, including surgery (excluding stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy;\n4. CNLC staging Ib IIIa stage, cannot be surgically removed;\n5. The maximum diameter of the tumor exceeds 5cm, and the number of tumors does not exceed 3 (1-3);\n6. Can merge portal vein cancer thrombus;\n7. Has not received any systemic anti-tumor therapy for the current stage of the disease in the past, including surgery (excluding stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy;\n8. Child Pugh score A5-B7;\n9. ECOG (Eastern Cooperative Oncology Group) Physical Status Score: 0-1 points;\n10. Expected survival period ≥ 3 months:\n11. The main organ function is good, which meets the following criteria (no blood components, cell growth factors, white blood boosting drugs, platelet boosting drugs, or anemia correcting drugs are allowed to be used within 14 days before enrollment):\n\nNeutrophils ≥ 1.5 × 109\u002FL; White blood cell count ≥ 3.0 × 109\u002FL; Platelets ≥ 100 × 109\u002FL; Hemoglobin ≥ 90g\u002FL; Serum albumin ≥ 34g\u002FL; Total bilirubin ≤ 1.5 × ULN (for patients with biliary obstruction receiving biliary drainage, it can be relaxed to\\\u003C2.5 × ULN); AST and ALT ≤ 2.5xULN (for patients with liver metastases, they can be relaxed to ≤ 5xULN); Creatinine clearance rate ≥ 60ml\u002Fmin or blood creatinine ≤ 1.5 × ULN; INR ≤ 1.5 × ULN and APTT ≤ 1.5 × ULN (for stable dose anticoagulant therapy such as low molecular weight heparin or warfarin, and INR can be screened within the expected therapeutic range of anticoagulants); Electrocardiogram: QTc ≤ 450ms (male), ≤ 470ms (female); Cardiac ultrasound: LVEF (left ventricular ejection fraction) ≥ 50%; 8) Women of childbearing age must undergo a blood pregnancy test within 7 days before enrollment, and the result must be negative. They must also be willing to use appropriate contraception methods during the trial period and for 6 months after the end of treatment. For males, surgical sterilization should be performed, or they should agree to use appropriate contraception methods during the study period and within 3 months after the end of treatment; 9) Voluntarily participate in this study and sign an informed consent form; Good compliance, agree to cooperate and receive survival follow-up;\n\nExclusion Criteria:\n\n1. Received any of the following treatments:\n\n   Previously received ICIs and\u002For HDACi treatment; Received the last anti-cancer treatment (including surgery, radiation therapy, etc.) within 4 weeks before enrollment; Received any other experimental drug\u002Fdevice treatment within 4 weeks prior to enrollment; Simultaneously enrolled in another clinical study, unless it is an observational (non interventional) clinical study or an interventional clinical study follow-up;\n2. Known patients who are allergic to the components of the investigational drug;\n3. Patients known to have central nervous system metastases;\n4. Severe gastrointestinal dysfunction (with bleeding, severe inflammation, obstruction, or diarrhea greater than grade 2);\n5. Serious infections (CTC AE\\>grade 2) occurred within the first 4 weeks of enrollment, such as severe pneumonia, bacteremia, and infection complications that require hospitalization. Symptoms and signs of infection within the first 2 weeks of enrollment require intravenous antibiotic treatment (excluding prophylactic use of antibiotics);\n6. Within the year prior to enrollment, there have been arterial\u002Fvenous thrombotic events such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism;\n7. Clinical symptoms or diseases of the heart that have not been well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within one year; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.\n8. Patients with malignant tumors other than liver cancer prior to the first use of the investigational drug are excluded, except for malignant tumors with low-risk metastasis and mortality risk (5-year survival rate\\>90%), such as fully treated cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma;\n9. Merge active hepatitis B (HBV DNA ≥ 2000IU\u002FmL or 104 copies\u002FmL) and hepatitis C (positive for hepatitis C antibodies);\n10. People who are known to have acquired immunodeficiency syndrome (AIDS) or HIV test positive, active syphilis infection;\n11. Having a clear history of neurological or mental disorders, including epilepsy or dementia:\n12. Planned pregnancy, pregnant and lactating women; According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study midway, such as non-compliance with the protocol, having other serious illnesses (including mental illnesses) that require concomitant treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of trial data, etc;",{"count":396,"type":23},34,[26],"This study is a single arm, single center, open label clinical trial. Recruit 34 subjects who meet the inclusion criteria and receive hepatic artery chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) combined with immune checkpoint inhibitors and donafenib treatment according to the study plan. The treatment cycle and dosage can be adjusted according to the patient's tolerance. Until disease progression or intolerable toxic reactions occur. Observe the effectiveness and safety indicators during the experimental process.",[400],"Unresectable Hepatocellular Carcinoma",[402,403,404,405,406],"transarterial chemoembolization (TACE)","stereotactic body radiotherapy (SBRT)","PD-1\u002FL1 inhibitor","donafenib","first-line therapy","2025-11-14",{"date":409,"type":40},"2025-11-17",{"date":411,"type":23},"2025-11-30",{"date":413,"type":23},"2027-11-30",{"name":46,"class":47},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":422,"targetDuration":4,"studyType":24,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":431,"leadSponsor":432,"locationsCount":48},"100529726","phase-2-adebrelimab-combined-with-chemotherapy-for-neoadjuvant-therapy-in-resectable-pancreatic-cancer-100529726","NCT06177522","Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","A Single-arm, Single-center, Exploratory Study of Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","inclusion criteria\n\n1. Age 18-80 years old, gender unlimited;\n2. Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 \\> 150 U\u002Fml);\n3. No previous systemic treatment for pancreatic cancer;\n4. Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is ≥10 mm, and the scan layer thickness is not more than 5 mm);\n5. ECOG score: 0 \\~ 1;\n6. Having adequate organ and bone marrow function, as defined below: Hemoglobin ≥9.0 g\u002FdL neutrophil absolute count ≥1.5×109\u002FL Platelet count ≥100×109\u002FL INR≤1.5 Total bilirubin (TBL) ≤1.5× upper limit of normal (ULN) AST and ALT≤2.5×ULN Serum albumin ≥3.0 g\u002FdL serum creatinine ≤1.5×ULN or measured creatinine clearance \\> 60 mL\u002Fmin or creatinine clearance \\> 60 mL\u002Fmin calculated according to the Cockcroft-Gault formula (using actual body weight) : Men: creatinine clearance =(weight x (140- age))\u002F(72 x serum creatinine) Women: Creatinine clearance =(body weight x (140-age))\u002F(72 x serum creatinine)x 0.85, where CL=mL\u002Fmin; Serum creatinine =mg\u002FdL;\n7. Patients with active HBV infection should receive antiviral therapy for more than 2 weeks according to local antiviral treatment guidelines before enrollment, and should continue treatment for 6 months after study drug therapy;\n8. A negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test at screening and a subsequent negative HCV RNA test;\n9. Expected survival ≥12 weeks;\n10. The investigator determined that the patient could receive adabilimab therapy;\n11. Subjects voluntarily participate in this study and sign informed consent.\n\nexclusion criteria\n\n1. Concurrent with other uncured malignant tumors;\n2. Subjects who have previously used PD-1\u002FPD-L1 antibodies;\n3. Subjects who can be surgically resected or treated with radical radiation;\n4. Subjects with a history of bleeding and any bleeding event with a severity rating of 3 or above on CTCAE4.0 within 4 weeks prior to screening;\n5. Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein quantity \\> 1.0g;\n6. Subjects with poorly controlled hypertension;\n7. Subjects who have experienced serious infection within 4 weeks prior to the first dose, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc. Subjects who developed a severe active infection requiring intravenous antibiotic treatment during screening;\n8. Subjects requiring systemic treatment with corticosteroids (\\>10 mg\u002F day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses \\> 10 mg\u002F day of prednisone efficacy;\n9. History of chronic autoimmune diseases, such as systemic lupus erythematosus, ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases; Except for hypothyroidism that requires only hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia);\n10. Subjects with grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for men and ≥470 ms for women). Subjects with NYHA standard Ⅲ \\~ Ⅳ cardiac insufficiency or LVEF (left ventricular ejection fraction) \\\u003C 50% were excluded;\n11. Subjects who are preparing for or have previously received tissue\u002Forgan transplants;\n12. Subjects who have received or will receive live vaccine within 30 days prior to the first dose;\n13. Subjects with a history of difficult to control mental illness or severe intellectual or cognitive impairment;\n14. Subjects with active hepatitis: hepatitis B virus surface antigen (HBV) positive with HBV DNA≥ 2000 IU\u002FmL, hepatitis C virus antibody (HCV Ab) positive, HCV RNA positive, abnormal liver function, combined with hepatitis B and hepatitis C co-infection;\n15. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n16. Allergic to the experimental drug;\n17. Women who are pregnant, breastfeeding or have given birth but refuse to use contraceptives;\n18. Other conditions deemed unsuitable for inclusion by the researchers.",{"count":423,"type":23},30,[26],"Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer",[427,428],"Pancreatic Cancer","Neoadjuvant Therapy",{"date":382,"type":40},{"date":411,"type":23},{"date":180,"type":23},{"name":46,"class":47},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":441,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":459},"100525215","ideal-study-blinded-rct-for-the-impact-of-ai-model-for-cerebral-aneurysms-detection-on-patients-diagnosis-and-outcomes-100525215","NCT06118840","IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes","Assessing the Impact of an Artificial Intelligence-Based Model for Intracranial Aneurysm Detection in CT Angiography on Patients' Diagnosis and Outcomes: The IDEAL Study - A Web-Based Multicenter, Double-Blinded Randomized Controlled Trial","IDEAL","Inclusion Criteria:\n\n* Adult inpatients and outpatients who are scheduled for head CTA scanning.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Patients with contraindications to CTA.\n* Modified Rankin Scale (mRS) score \\> 3.\n* Refuse to sign informed consent.\n* Participation in other clinical studies of intracranial aneurysms.\n* Patients with failed head CTA scanning or incomplete image data, or poor image quality.",true,{"count":443,"type":23},6450,[113],"This study (IEDAL study) intends to prospectively enroll more than 6450 patients who will undergo head CT angiography (CTA) scanning in the outpatient clinic. It will be carried out in 21 hospitals in more than 10 provinces in China. The patient's head CTA images will be randomly assigned to the True-AI and Sham-AI group with a ratio of 1:1, and the patients and radiologists are unaware of the allocation. The primary outcomes are sensitivity and specificity of detecting intracranial aneurysms. The secondary outcomes focus on the prognosis and outcomes of the patients.",[447,448,449,450],"Intracranial Aneurysm","CT Angiography","Deep Learning","Double Bind Interaction","2025-10-01",{"date":453,"type":40},"2025-10-07",{"date":455,"type":40},"2024-05-20",{"date":457,"type":23},"2026-12",{"name":46,"class":47},21,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":24,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":48},"100606432","phase-2-petct-directed-free-of-therapy-for-metastatic-rcc-patients-with-imdc-favorable-or-intermediate-risk-100606432","NCT07175480","PET\u002FCT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk","An Open-label, Investigator-initiated, Single Arm, Exploratory Phase 2 Trial Evaluating the Feasibility and Efficiency of PET\u002FCT Directed Free of Therapy Used for Metastatic and Advanced Renal Cell Carcinoma","Perfumer","Pre-screening Inclusion Criteria:\n\n1. Male or female subjects aged ≥ 18 years at time of signing informed consent\n2. Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC (American Joint Committee on Cancer \\[AJCC\\] Stage IV)\n3. Favorable or intermediate risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. Eastern Cooperative Oncology Group performance status 0 or 1\n5. Karnofsky Performance Status (KPS) grade ≥ 70%\n6. Adequate organ and bone marrow function meeting all laboratory criteria:\n\n   Ⅰ. Absolute neutrophil count (ANC) ≥ 1.5 × 10³\u002FμL (≥ 1.5 GI\u002FL); Platelet count ≥ 100 × 10³\u002FμL (≥ 100 GI\u002FL); Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL)\n\n   Ⅱ. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × upper limit of normal. Total bilirubin ≤ 1.5 × the upper limit of normal (≤ 3 mg\u002FdL \\[≤ 51.3 μmol\u002FL\\] if Gilbert's syndrome)\n\n   Ⅲ. Serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥ 30 mL\u002Fmin using the Cockroft-Gault formula.\n7. Capacity to comprehend and comply with protocol requirements, with documented informed consent signed\n8. Contraception agreement for sexually active fertile participants and partners to use of medically accepted methods during study and continue for 5 months after last treatment\n9. Negative pregnancy status at screening for women of childbearing potential\n\nPre-screening Exclusion Criteria:\n\n1. Highly malignant pathology\n2. Prior systemic therapy for advanced RCC\n3. Poor risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. ECOG performance status \\>1\n5. Karnofsky Performance Status (KPS) \\\u003C70%\n6. Inadequate organ and bone marrow function\n7. Bulky or symptomatic disease or hepatic metastases\n8. Active brain metastases or leptomeningeal disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 3 months before the start of treatment.\n9. Concurrent or prior invasive malignancies that could confound efficacy assessment, except adequately treated non-melanoma skin cancer, superficial bladder cancer or carcinoma in situ of the cervix\u002Fbreast with curative therapy \\>3 years ago.\n10. Uncontrolled hypertension (\\>150\u002F100 mmHg despite optimal therapy)\n11. Uncontrolled comorbidities within 6 months including but not limited to: clinically significant cardiovascular disorders, gastrointestinal disorders with high risk of perforation or fistula formation, significant hematuria, hematemesis, hemoptysis, or major bleeding history, severe infections, severe autoimmune diseases (e.g., systemic lupus erythematosus, immune pneumonitis), active HIV, HBV, or HCV infections.\n12. Major surgery within 4 weeks with unhealed wounds or planned surgery during study\n13. Concomitant use of drugs or substances affecting activity or pharmacokinetics of investigational products\n14. Hypersensitivity to any component of study drugs\n15. Chronic or concurrent immunosuppressive therapy, except Inhaled\u002Ftopical steroids\n16. Medical\u002Fpsychiatric\u002Fsocial conditions compromising protocol compliance\n17. Pregnancy, lactation, or refusal of contraception during and for 5 months post-treatment\n18. Inability to undergo PET\u002FCT or oral drug administration\n\nMain-screening Inclusion Criteria:\n\n1. Patient must receive≥12 months of first line treatment with the combination of PD-1\u002FPD-L1 ICI and VEGFR-TKI, and have not experienced a toxicity that prevents them from continuing on therapy.\n2. Patients must achieve complete metabolic response (CMR) or partial metabolic response (PMR) on PET\u002FCT within 24 months of the combination treatment with PD-1\u002FPD-L1 ICI and VEGFR-TKI.\n3. Favorable or intermediate risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. Eastern Cooperative Oncology Group performance status 0 or 1\n5. Karnofsky Performance Status (KPS) grade ≥ 70%\n6. Adequate organ and bone marrow function meeting all laboratory criteria:\n\n   Ⅰ. Absolute neutrophil count (ANC) ≥ 1.5 × 10³\u002FμL (≥ 1.5 GI\u002FL); Platelet count ≥ 100 × 10³\u002FμL (≥ 100 GI\u002FL); Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL)\n\n   Ⅱ. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × upper limit of normal. Total bilirubin ≤ 1.5 × the upper limit of normal (≤ 3 mg\u002FdL \\[≤ 51.3 μmol\u002FL\\] if Gilbert's syndrome)\n\n   Ⅲ. Serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥ 30 mL\u002Fmin using the Cockroft-Gault formula.\n7. Capacity to comprehend and comply with protocol requirements, with documented informed consent signed\n8. Contraception agreement for sexually active fertile participants and partners to use of medically accepted methods during study and continue for 5 months after last treatment\n9. Negative pregnancy status at screening for women of childbearing potential\n\nMain-screening Exclusion Criteria:\n\n1. Failure to complete ≥12 months of first-line PD-1\u002FPD-L1 + VEGFR-TKI therapy due to unmanageable toxicity or other reasons\n2. Failure to achieve CMR or PMR on PET\u002FCT within 24 months after combination therapy; new metastatic lesions or disease progression on PET\u002FCT.\n3. Poor risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. ECOG performance status \\>1\n5. Karnofsky Performance Status (KPS) \\\u003C70%\n6. Inadequate organ and bone marrow function\n7. Uncontrolled hypertension (\\>150\u002F100 mmHg despite optimal therapy)\n8. Uncontrolled comorbidities including but not limited to: clinically significant cardiovascular disorders, gastrointestinal disorders with high risk of perforation or fistula formation, significant hematuria, hematemesis, hemoptysis, or major bleeding history, severe infections, severe autoimmune diseases (e.g., systemic lupus erythematosus, immune pneumonitis), active HIV, HBV, or HCV infections.\n9. Medical\u002Fpsychiatric\u002Fsocial conditions compromising protocol compliance\n10. Pregnancy, lactation, or refusal of contraception during study period.\n11. Inability to undergo PET\u002FCT or oral drug administration\n\nWithdrawal Criteria:\n\n1. Disease progression with unsatisfactory efficacy, or occurrence of intercurrent illnesses during treatment or follow-up period.\n2. Occurrence of severe treatment-related adverse reactions.\n3. Laboratory test results indicating critical safety values.\n4. Voluntary withdrawal of informed consent by the patient.\n5. Investigator's judgment that withdrawal is in the subject's best interest.\n6. Pregnancy during the trial period.\n7. Wrong Enrollees: deviation of inclusion or exclusion criteria.\n8. Poor patient compliance.\n9. Loss to follow-up or death during the trial period.",{"count":423,"type":23},[26],"This phase 2 trial aims to test the feasibility and efficiency of PET\u002FCT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable\u002Fintermediate risk who achieve complete (CMR) or partial metabolic response (PMR) after ≥12 months of first-line PD-1\u002FPD-L1 Immune checkpoint inhibitor (ICI)+ VEGFR-tyrosine kinase inhibitor (TKI) therapy. It helps figure out whether PET\u002FCT can safely direct treatment pause as well as explores a new individualized treatment option based on metabolic imaging for RCC patients.",[472,473],"Renal Cell Carcinoma (RCC)","Metastatic Renal Cell Carcinoma (mRCC)","2025-09-08",{"date":476,"type":40},"2025-09-16",{"date":478,"type":40},"2025-01-24",{"date":480,"type":23},"2030-08",{"name":46,"class":47},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":489,"targetDuration":4,"studyType":24,"phases":491,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":48},"100535699","phase-2-a-study-of-multimodal-radiotherapy-for-renal-cell-carcinoma-progressed-after-prior-immunotherapy-100535699","NCT06255223","A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy","An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy","Inclusion Criteria:\n\n* Renal cell carcinoma confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma.\n* Subject's previous treatment: Disease progression or intolerance following prior treatment with 1-2 systemic therapies (at least one regimen containing immune checkpoint inhibitors, including combined VEGFR-TKI drugs), And patients who have progressed within 12 months of prior immunoadjuvant or neoadjuvant therapy; According to the evaluation of attending physicians and professional radiotherapy doctors, it meets the standard of radiotherapy.\n* Patients can tolerate sequential immunotherapy while receiving radiation therapy.\n* At least two or more metastases at different sites are considered observable according to RECIST v1.1.\n* Subjects have fully understood and voluntarily signed an informed Consent form (ICF).\n* ECOG 0-1 points.\n* Major organs are functioning well.\n* Willing and able to comply with study plan visits, treatment laboratory tests, sample retention, and other procedures.\n* Fertile women must voluntarily use a highly effective contraceptive method (e.g., oral, injectable or implantable, barrier method, spermicide and condom, or intrauterine device) from the study period to ≥120 days after the last dose and have negative urine or serum pregnancy test results ≤7 days prior to enrolment.\n* Male patients who are not sterilized must voluntarily use highly effective contraception during the study period until ≥120 days after the last dose.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery).\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy, was administered 4 weeks prior to the first study.\n* Previous history of radiation therapy at any site or in any mode.\n* Had major surgery (as judged by the investigator) within 4 weeks prior to the first trial or was convalescing.\n* A history of severe drug allergy, including but not limited to antibody drugs.\n* Patients with contraindications to restart immunotherapy.\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy.\n* Patients with thyroid, suprarenal, or hypopituitarism that can be controlled with hormone replacement therapy alone, type 1 diabetes, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study.\n* Toxicity did not resolve after previous antitumor therapy, i.e. regression to baseline, prescribed grade 0 to 1 (except alopecia) as defined in NCI-CTCAE 5.0, or to the levels specified in the inclusion\u002Fexclusion criteria. Irreversible toxicity (such as hearing loss) that could reasonably be expected not to be aggravated by the drug under study could be included in this study.\n* Have central nervous system metastases and\u002For cancerous meningitis.\n* A known history of clinically significant liver disease.\n* Accompanied by uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc.\n* In the first study, systemic corticosteroids or other immunosuppressive drugs were administered within 14 days prior to medication.\n* Patients with any severe or uncontrolled disease.\n* Have or have a suspected presence of active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.\n* Renal failure requires hemodialysis or peritoneal dialysis.\n* A history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation.\n* History of live attenuated vaccine vaccination within 4 weeks prior to administration or expected live attenuated vaccine vaccination during the study period was studied for the first time.\n* People who have a history of psychotropic substance abuse and cannot abstain or have a history of mental disorders.\n* Pregnant or lactating women.\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.",{"count":490,"type":23},35,[26],"The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.",[359,494,495],"Radiotherapy","Immune Checkpoint Inhibitor",[360,497],"Multimodal radiotherapy","2025-08-26",{"date":500,"type":40},"2025-09-03",{"date":502,"type":40},"2023-12-15",{"date":346,"type":23},{"name":46,"class":47},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":441,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":24,"phases":515,"briefSummary":516,"conditions":517,"keywords":520,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":4},"100602523","stepped-wedge-cluster-randomized-trial-of-ai-assisted-cta-detection-for-intracranial-aneurysms-in-regional-hospitals-100602523","NCT07124624","Stepped-Wedge Cluster Randomized Trial of AI-Assisted CTA Detection for Intracranial Aneurysms in Regional Hospitals","Impact of an AI-Driven CT Angiography Model on Intracranial Aneurysm Detection and Clinical Outcomes in Regional Hospitals (IDEAL2): A Nationwide Stepped-Wedge Cluster-Randomized Trial","IDEAL2","Inclusion Criteria:\n\n-Patients in the outpatient setting who are scheduled to undergo head CTA scanning\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* History of cerebrovascular surgery involving any metallic implants (e.g., aneurysm embolization, aneurysm clipping, or vascular stenting)\n* Modified Rankin Scale (mRS) score \\> 3\n* Refuse to sign written informed consent\n* Contraindications to CTA examination\n* CTA scan failure, incomplete imaging data, or image quality insufficient for diagnostic evaluation",{"count":514,"type":23},14400,[113],"This study (IDEAL 2) is a nationwide stepped-wedge cluster-randomized trial designed to prospectively enroll over 14,400 patients undergoing outpatient head CT angiography (CTA). The trial will be conducted across more than 72 regional hospitals in China. Clusters were randomly assigned to nine randomization groups. In accordance with the stepped-wedge design, clusters will sequentially transition from the control condition (standard human diagnosis) to the intervention condition (AI-assisted diagnosis) at regular intervals over a 10-month period, until all clusters receive the intervention. The primary outcome is the detection rate of intracranial aneurysms. Secondary outcomes include patient prognosis and clinical outcomes.",[447,448,518,519],"AI (Artificial Intelligence)","Cluster Randomized Trial",[521,518,522],"Intracranial aneurysm","Stepped-wedge cluster-randomized trial","2025-08-15",{"date":525,"type":40},"2025-08-20",{"date":527,"type":23},"2025-10-09",{"date":529,"type":23},"2029-08-31",{"name":46,"class":47},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":441,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":266,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":48},"100584802","dongzong-cardiovascular-bio-imaging-registry-study-100584802","NCT06894095","Dongzong Cardiovascular Bio-imaging Registry Study","DAILY","Inclusion Criteria:\n\n* Aged ≥18 years\n* Coronary CT angiography performed\n* Informed consent acquired\n\nExclusion Criteria:\n\n* Unable to complete the follow-up\n* Serious chronic kidney disease (eGFR\\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n* Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 3 times the upper limit of normal)\n* Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc.\n* Suspected or known infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV)\u002Facquired immunodeficiency syndrome (AIDS), and Treponema pallidum (syphilis), etc.",{"count":539,"type":23},50000,"The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imaging database that integrates multidimensional data, including living environments, psychosocial and cognitive assessments, advanced lung and cardiovascular imaging, multi-omics profiles, clinical medication and surgical records, and health outcomes. Leveraging this extensive, multiscale dataset, the project aims to elucidate the intricate interplay between genetic biology and environmental factors in driving downstream biological alterations, thereby shaping lung and cardiovascular structural and functional phenotypes, and ultimately influencing the onset and progression of cardiovascular diseases (CVD). Through a systematic exploration and understanding of this complex network, the project seeks to identify critical intervention points and develop innovative strategies for the prevention and management of CVD.",[542,543,544,545],"Cardiovascular Diseases","Multi-omics","Living Environments","Pulmonary-cardiovascular Imaging","2025-03-19",{"date":548,"type":40},"2025-03-25",{"date":550,"type":40},"2023-05-24",{"date":552,"type":23},"2038-05-31",{"name":46,"class":47},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":24,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":48},"100509724","phase-2-a-study-of-rc48-adc-combined-with-js001-for-postoperative-adjuvant-treatment-of-upper-tract-urothelial-carcinoma-100509724","NCT05917158","A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma","An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of RC48-ADC Combined with JS001 in Postoperative Adjuvant Treatment of HER2-positive Upper Tract Urothelial Carcinoma (UTUC)","1","Inclusion Criteria:\n\n* Written informed consent\n* ≥18 years of age\n* Post radical nephro-ureterectomy for upper tract tumour with predominant TCC component-squamoid differentiation or mixed TCC\u002FSCC is permitted.\n* Histologically confirmed TCC staged pT2-pT4 pN0-2 M0 or pTany N1-2 M0 (providing all grossly abnormal nodes are resected).\n* Pathological tissue immunohistochemistry HER2 2\\~3+\n* Fit and willing to receive adjuvant therapy with first cycle to be commenced within 90 days of radical nephro-ureterectomy if allocated\n* ECOG(Eastern Cooperative Oncology Group) performance is 0\\~2.\n* Available for long-term follow-up\n\nExclusion Criteria:\n\n* Evidence of distant metastases\n* Pure adenocarcinoma, squamous cell carcinoma or small cell or other variant histology\n* Un-resected macroscopic nodal disease\n* Concurrent muscle invasive bladder cancer (patients with concurrent Non-muscle invasive bladder cancer (NMIBC) will be eligible)\n* Significant co-morbid conditions that would interfere with administration of protocol treatment\n* Pregnancy; lactating women or women of childbearing potential unwilling or unable to use adequate non-hormonal contraception (male patients should also use contraception if sexually active);\n* Previous malignancy in the last 5 years except for previous NMIBC, adequately controlled non melanoma skin tumours, CIS of cervix or LCIS of breast or localised prostate cancer in patients who have a life expectancy of over 5 years upon trial entry.",{"count":423,"type":23},[26],"This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.",[333,566,567],"Upper Tract Urothelial Carcinoma","UTUC","2025-01-20",{"date":570,"type":40},"2025-01-22",{"date":572,"type":40},"2022-11-23",{"date":574,"type":23},"2028-12",{"name":46,"class":47},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":592,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":48},"100563718","hyperbaric-oxygen-therapy-for-metabolic-dysfunction-associated-steatotic-liver-diseases-100563718","NCT06619808","Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases","Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial","MASLD","Inclusion Criteria:\n\n* Metabolic dysfunction-associated steatotic liver disease patients\n\nExclusion Criteria:\n\n* Participants are unfit for hyperbaric treatment.\n* Participants with prior oxygen therapy within the last 6 months.\n* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.\n* Participants with severe organ dysfunctions or malignant tumors.\n* Participants have weight loss plan or major operations within the last 6 months.\n* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.\n* Participants are pregnant or lactating.\n* Participants with claustrophobia or that cannot decompress properly.",{"count":585,"type":23},150,[113],"The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:\n\nDoes HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?\n\nParticipants will:\n\nReceive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.",[589,590,591],"Metabolic Dysfunction-associated Steatotic Liver Disease","Hepatic Steatosis","Non-alcoholic Fatty Liver Diseases",[589,593,591,594],"Hyperbaric Oxygen Therapy","Oxygen Therapy","2024-09-28",{"date":597,"type":40},"2024-10-01",{"date":599,"type":40},"2024-07-29",{"date":601,"type":23},"2026-08-31",{"name":46,"class":47},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":441,"sex":18,"minAge":610,"maxAge":109,"enrollmentInfo":611,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":131},"100563149","early-phase-1-bsubtilis-attenuate-symptoms-in-diarrhea-predominant-irritable-bowel-syndrome-by-increasing-hypoxanthine-biosynthesis-100563149","NCT06612411","B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis","Purine Starvation Driven by Host-microbiota Maladaptation Contributes to the Pathogenesis of Irritable Bowel Syndrome","Inclusion Criteria:\n\nPatients are diagnosed with IBS. IBS was diagnosed based on the Rome IV criteria. Subjects aged from 16-80 years old without any gut medical conditions like inflammatory bowel diseases, infectious diarrhea, colon tumors were included.\n\nExclusion Criteria:\n\nSubjects who are taking any probiotics, PPIs, antibiotics or any drugs affecting uric acid levels for at least one month before the study.\n\nSubjects who decline to participate into the study.","16 Years",{"count":612,"type":23},180,[614],"EARLY_PHASE1","This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.",[617,618],"Irritable Bowel Syndrome with Diarrhea","Purine Metabolism Disorder","2024-09-24",{"date":621,"type":40},"2024-09-25",{"date":623,"type":40},"2024-06-01",{"date":625,"type":23},"2024-12-31",{"name":46,"class":47},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":635,"targetDuration":4,"studyType":24,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":4},"100499339","effect-of-nutritional-support-and-early-rehabilitation-on-sepsis-100499339","NCT05781971","Effect of Nutritional Support and Early Rehabilitation on Sepsis","Department of Intensive Care Medicine, The First Affiliated Hospital of Soochow University","NUSPOTER","Inclusion Standard\n\n1. Patients with sepsis\n2. Patients aged 18-70 years\n3. Time of admission ≤48 h\n4. Non-terminal condition\n\nExclusion Standard\n\n1. Severe acute kidney injury\n2. Severe chronic liver disease (MELD score ≥20) or acute hepatic failure\n3. Protein allergy\n4. Pregnancy and lactation\n5. BMI≥30 kg\u002Fm²",{"count":636,"type":23},1600,[113],"Sepsis is a syndrome of life-threatening organ dysfunction caused by a dysregulated host response to infection.Acute catabolic response in critically ill patients struck by sepsis, manifested by massive protein breakdown in a short time.This pathology frequently leads to prolonged hospitalization and mechanical ventilation, increased mortality, and reduced quality of survival.It is uncertainty whether sepsis patients in ICU can benefit from high protein intake combined with early exercise. Even though the combination has been shown to be beneficial in other populations.In the present study, the investigator will evaluate the effects of a combination of high protein targets combined with early rehabilitation in sepsis patients in ICU.",[640,641],"Life Quality","Hospital Mortality","2024-06-14",{"date":644,"type":40},"2024-06-17",{"date":646,"type":23},"2024-12-01",{"date":648,"type":23},"2026-05",{"name":46,"class":47},""]